Skip to main content
. 2022 Mar 30;3(5):100316. doi: 10.1016/j.jtocrr.2022.100316

Figure 1.

Figure 1

(A) Real-world PFS and (B) OS according to durvalumab dosing schedule. Data cutoff was July 23, 2021. Median follow-up was 19.7 months (2-weekly group) versus 12.0 months (4-weekly group). PFS was defined as the time from durvalumab start to progression or death. OS was defined as time from durvalumab start to death. CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.